FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Fulgent Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$20.10+0.29 (+1.46%)
Close on Oct 19, 2026
- Market cap
- $562.90M
- P/E (TTM)
- –
- Dividend yield
- –
Fulgent Genetics, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services | $85.36M | $71.05M | $83.03M | $83.93M | $81.80M | $73.46M | $76.21M | $71.74M | $71.03M | $64.49M | $70.51M | $84.69M | 100.0% | +4.3% |
| Therapeutic Development | $30.00K | $87.00K | $309.00K | $138.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | 0.0% | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Development | -$4.96M | -$4.46M | -$4.72M | -$6.00M | -$4.88M | -$4.25M | -$4.44M | -$3.82M | -$4.74M | -$5.04M | $2.42M | -$3.35M | +1.8% |
| Laboratory Services | -$17.44M | -$15.22M | -$4.18M | $2.49M | -$2.81M | -$3.00M | $706.00K | -$348.00K | -$543.00K | -$16.75M | $17.46M | $3.57M | +521.2% |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $78.29M | $65.11M | $74.91M | $77.61M | $76.21M | $67.83M | $70.08M | $65.70M | $64.19M | $57.85M | $64.89M | $78.97M | 91.7% | +2.7% |
| Foreign | $7.10M | $6.03M | $8.43M | $6.46M | $5.60M | $5.64M | $6.13M | $6.04M | $6.83M | $6.64M | $5.62M | $5.71M | 8.3% | +26.8% |
| Other countries | $4.05M | $3.47M | $3.67M | $3.33M | $3.19M | $3.03M | $2.86M | $3.26M | $4.36M | $2.53M | $2.38M | $2.29M | 4.7% | +26.8% |
| China | $3.08M | $2.56M | $4.76M | $3.13M | $2.41M | $2.61M | $3.27M | $2.79M | $2.48M | $4.10M | $3.24M | $3.43M | 3.6% | +28.0% |
From the segment and revenue-disaggregation notes of Fulgent Genetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.